Na Li Lab

Na Li Lab Publications

Master
Heading

Selected Publications

Heading

2019

Content

Ni L, Scott L Jr, Campbell HM, Pan X, Alsina KM, Reynolds J, Philippen LE, Hulsurkar M, Lagor WR, Li N, Wehrens XHT. Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector. Circ Res. 2019;124(2):256-262.

Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I Dr, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Müller FU, El-Armouche A, Tony Eissa N, Beeton C, Nattel S, Wehrens XHT, Dobrev D, Li N. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018; 138(20):2227-2242.

Li N, Wang Q, Sibrian-Vazquez M, Klipp RC, Reynolds JO, Word TA, Scott L Jr, Salama G, Strongin RM, Abramson JJ, Wehrens XHT. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017 Jan 15;227:668-673.

Chiang DY, Zhang M, Voigt N, Alsina KM, Jakob H, Martin JF, Dobrev D, Wehrens XH, Li N. Identification of microRNA-mRNA dysregulations in paroxysmal atrial fibrillation. Int J Cardiol. 2015 Apr 1;184:190-7

Chiang DY, Kongchan N, Beavers DL, Alsina KM, Voigt N, Neilson JR, Jakob H, Martin JF, Dobrev D, Wehrens XH, Li N.Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1214-22

Li N, Chiang DY, Wang S, Wang Q, Sun L, Voigt N, Respress JL, Ather S, Skapura DG, Jordan VK, Horrigan FT, Schmitz W, Müller FU, Valderrabano M, Nattel S, Dobrev D, Wehrens XHT. Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. Circulation. 2014 Mar 25;129(12):1276-1285

Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XH. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. Circ Res. 2012 Feb 3;110(3):465-70

Heading

2018

Content

Scott L Jr, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2018 Oct 4. [Epub ahead of print] Review.

Chelu MG, Li N. "Sorting" SERCA2a: A novel therapeutic strategy in heart failure? Int J Cardiol. 2018 Aug 18. [Epub ahead of print]

Chen G, Chelu MG, Dobrev D, Li N. Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications. Front Physiol. 2018; 9:1115.

Yao C, Veleva T, Scott Jr. L, Cao S, Li L, Gong C, Jeyabal P, Pan X, Alsina KM, Ghezelbash S, Abu-Taha I, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Müller FU, El-Armouche A, Eissa NT, Beeton C, Nattel S, Wehrens XH, Dobrev D, Li N. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018 May 25. [Epub ahead of print]

Chelu MG, Li N. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: are we there yet? Int J Cardiol. 2018; 267:116-7.

Lai YC, Li N, Lawrence W, Wang S, Levine A, Pautler R, Valderrábano M, Wehrens XH, Anderson A. Myocardial remodeling and susceptibility to ventricular tachycardia in a model of chronic epilepsy. Epilepsia Open. 2018; 3:213-23.

Li N, Dobromir Dobrev. Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure? Naunyn Schmiedebergs Arch Pharmacol. 2018; 391:231-3.

Heading

Editorial & Review Articles

Content

Suryavanshi SV, Li N. Behçet's disease: A (silk) route to atrial fibrillation? Int J Cardiol. 2019 Jul 19. pii: S0167-5273(19) 33157-2. [Epub ahead of print]

Scott L Jr, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2018 Oct 4;. doi: 10.1016/j.ijcard.2018.10.020.

Chelu MG, Li N. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: Are we there yet?. Int J Cardiol. 2018; 267:116-117 .

Chen G, Chelu MG, Dobrev D, Li N. Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications. Front Physiol. 2018;9:1115. doi: 10.3389/fphys.2018.01115. eCollection.

Li N, Dobrev D. Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure?Naunyn Schmiedebergs Arch Pharmacol. 2018;391(3):231-233.

Li N, Dobrev D. Hyperuricemia: A causal player or a bystander linking inflammatory signaling and atrial fibrillation? Int J Cardiol. 2017; 231:177-178.

Li N. Editorial Commentary: The emerging role of epigenetics in atrial fibrillation. Trends Cardiovasc Med. 2016;26(4):319-20.

Li N, Dobrev D, Wehrens XH. PITX2: a master regulator of cardiac channelopathy in atrial fibrillation?. Cardiovasc Res. 2016;109(3):345-7